Technical Analysis for ONCE - Spark Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
![]() |
51.09 | -3.18% | -1.68 |
ONCE closed down 3.18 percent on Tuesday, February 19, 2019, on 1.91 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
ADX | Long-Term | Intermediate-Term | Short-Term |
---|---|---|---|
Strong | Down | Up | Up |
See historical ONCE trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Feb 19 | Slingshot Bullish | Bullish Swing Setup | 0.00% |
Feb 19 | Upper Bollinger Band Walk | Strength | 0.00% |
Feb 19 | Earnings Movers | Other | 0.00% |
Feb 19 | Multiple of Ten Bullish | Other | 0.00% |
Feb 19 | Weak + Overbought | Other | 0.00% |
Feb 19 | Outside Day | Range Expansion | 0.00% |
Feb 19 | Overbought Stochastic | Strength | 0.00% |
Feb 19 | Upper Bollinger Band Touch | Strength | 0.00% |
Feb 15 | Above Upper BB | Strength | -3.18% |
Feb 15 | Overbought Stochastic | Strength | -3.18% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-19
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Biology Emerging Technologies Gene Therapy Molecular Biology Medical Genetics Neurodegenerative Diseases Retinitis Pigmentosa Blindness Gene Delivery Treatment Of Hemophilia Gene Therapy Products Genetic Diseases Hemophilia A Choroideremia Genetic Disorder Hemophilia B
Biology Emerging Technologies Gene Therapy Molecular Biology Medical Genetics Neurodegenerative Diseases Retinitis Pigmentosa Blindness Gene Delivery Treatment Of Hemophilia Gene Therapy Products Genetic Diseases Hemophilia A Choroideremia Genetic Disorder Hemophilia B
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength | |||
Summary: | Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. |
See more ONCE news...
Indicators
Indicator | Value |
---|---|
52 Week High | 96.59 |
52 Week Low | 34.53 |
Average Volume | 523,371 |
200-Day Moving Average | 58.8308 |
50-Day Moving Average | 43.146 |
20-Day Moving Average | 46.783 |
10-Day Moving Average | 49.051 |
Average True Range | 2.3103 |
ADX | 32.36 |
+DI | 29.6917 |
-DI | 9.612 |
Chandelier Exit (Long, 3 ATRs ) | 46.3391 |
Chandelier Exit (Short, 3 ATRs ) | 47.5709 |
Upper Bollinger Band | 53.1015 |
Lower Bollinger Band | 40.4645 |
Percent B (%b) | 0.84 |
BandWidth | 27.011949 |
MACD Line | 2.2431 |
MACD Signal Line | 1.8355 |
MACD Histogram | 0.4076 |
Fundamentals | Value |
---|---|
Market Cap | 1.6 Billion |
Num Shares | 31.3 Million |
EPS | -6.39 |
Price-to-Earnings (P/E) Ratio | -8.00 |
Price-to-Sales | 124.29 |
Price-to-Book | 11.08 |
PEG Ratio | -0.59 |
Dividend | 0.00 |
Dividend Yield | 0.00% |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 56.73 | ||||
Resistance 3 (R3) | 56.83 | 55.05 | 55.79 | ||
Resistance 2 (R2) | 55.05 | 53.61 | 55.00 | 55.48 | |
Resistance 1 (R1) | 53.07 | 52.73 | 52.18 | 52.97 | 55.16 |
Pivot Point | 51.29 | 51.29 | 50.85 | 51.24 | 51.29 |
Support 1 (S1) | 49.31 | 49.85 | 48.42 | 49.21 | 47.02 |
Support 2 (S2) | 47.53 | 48.97 | 47.48 | 46.70 | |
Support 3 (S3) | 45.55 | 47.53 | 46.39 | ||
Support 4 (S4) | 45.45 |